U.S. must develop plan to protect clinical trials as national security asset
Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and generate soft power through health diplomacy.
Related Articles
In internal call, CDC employees recount shooting, ask about RFK Jr.’s response
After a gunman shot up CDC headquarters, employees had harrowing stories and questions about “disinformation that caused this issue.”
In internal call, CDC employees recount shooting, ask about RFK Jr.’s response
After a gunman shot up CDC headquarters, employees had harrowing stories and questions about “disinformation that caused this issue.”
Vinay Prasad returns to the FDA, weeks after his ouster
HFO HFO Vinay Prasad returns to a top FDA role just weeks after his abrupt dismissal.
Former surgeon general: The CDC shooting must be a wakeup call
“When influential figures amplify falsehoods, they legitimize the anger that leads to violence,” writes former Surgeon General Jerome Adams.
Former surgeon general: The CDC shooting must be a wakeup call
“When influential figures amplify falsehoods, they legitimize the anger that leads to violence,” writes former Surgeon General Jerome Adams.
Kennedy’s rejection of mRNA vaccines thwarts scientific progress — and threatens national security, experts say
Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding for mRNA vaccines has alarmed scientists. But it is also a matter of national security,…
Vinay Prasad returns to the FDA, weeks after his ouster
HFO HFO Vinay Prasad returns to a top FDA role just weeks after his abrupt dismissal.
HHS cites list of studies as scientific justification for cancellation of mRNA vaccine contracts
HHS officials are citing an extensive list of studies purported to document harms caused by mRNA vaccines as scientific justification for canceling contracts.
Superagers’ brains offer clues to cognitive resilience, and possible treatments, researchers say
Some octogenarians have exceptionally sharp memories, even sharper than people who are decades younger. A new analysis of their brains could help explain why.
Vinay Prasad returns to the FDA, weeks after his ouster
HFO HFO Vinay Prasad returns to a top FDA role just weeks after his abrupt dismissal.